ClinicalTrials.gg
RecruitingNCT05200923PEER 2Updated Oct 13, 2026

Pelvic Health Electrically Evoked Recording (PEER) 2 Study

An interventional study of Sacral Neuromodulation in Overactive Bladder, Fecal Incontinence and Urinary Retention, sponsored by MedtronicNeuro. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by MedtronicNeuro (part of Medtronic) · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 333 studies in Urinary Bladder, Overactive with a site in United States — 40 open to participants now, 48 under way, 2 of them phase 3. Urinary Bladder, Overactive · United States.

Planned enrollment
57th of 288
300 · median 66
Started
2022
with 12 others
No phase
113 of 333
20 open now
Primary completion
2026-12
later than 18 of 47 live
Registered
261st of 333
by date

Among the 333 studies in Urinary Bladder, Overactive with a site in United States, this one is the 57th largest by planned enrollment of the 288 interventional ones that give a count, is one of 13 that started in 2022, is one of 113 with no phase, reaches primary completion later than 18 of the 47 other live ones, and was the 261st registered.

Urinary Bladder, Overactive

860 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

40 of the 333 studies in Urinary Bladder, Overactive with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Urinary Bladder, Overactive with a site in United States, or all of them as a file.
02

Study summary

To collect physiological signals at several timepoints during the therapy evaluation period.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this non-applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

03

Conditions studied

  • Overactive Bladder
  • Fecal Incontinence
  • Urinary Retention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Overactive Bladder Criteria Inclusion Criteria

  1. 18 years of age or older
  2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation
  3. Willing and able to provide signed and dated
  4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  5. Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation
  6. For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary.
  7. For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary.

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Non-Obstructive Urinary Retention Inclusion Criteria

  1. 18 years of age or older
  2. Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation
  3. Willing and able to provide signed and dated informed consent
  4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  5. Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation
  6. Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions.

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Fecal Incontinence Inclusion Criteria

  1. 18 years of age or older
  2. Candidate for or undergoing Medtronic InterStim lead implant labeled indication* requiring an advanced evaluation
  3. Willing and able to provide signed and dated informed consent
  4. Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
  5. Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation
  6. Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling)

Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.

Exclusion criteria

Exclusion Criteria:

Overactive Bladder Criteria Exclusion Criteria

  1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  2. Implanted with a neurostimulator, pacemaker or defibrillator
  3. Pelvic floor muscle dysfunction due to surgical intervention or injury
  4. Have neurological conditions such as multiple sclerosis, peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  5. History of diabetes unless the diabetes is well-controlled through diet and/or medications
  6. Have symptomatic urinary tract infection (UTI)
  7. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
  8. Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study
  9. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  10. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  11. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  12. Women who are pregnant or planning to become pregnant
  13. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
  14. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Non-Obstructive Urinary Retention Exclusion Criteria

  1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  2. Implanted with a neurostimulator, pacemaker or defibrillator
  3. Pelvic floor muscle dysfunction due to surgical intervention or injury
  4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  5. History of diabetes unless the diabetes is well-controlled through diet and/or medications
  6. Have symptomatic urinary tract infection (UTI)
  7. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  8. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  9. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  10. Women who are pregnant or planning to become pregnant
  11. Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
  12. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements

Fecal Incontinence Exclusion Criteria

  1. Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
  2. Implanted with a neurostimulator, pacemaker or defibrillator
  3. Pelvic floor muscle dysfunction due to surgical intervention or injury
  4. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
  5. Have uncorrected high grade internal rectal prolapse
  6. Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
  7. Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
  8. Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
  9. Women who are pregnant or planning to become pregnant
  10. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Pelvic health Electrically Evoked Recording (PEER) 2 Study

    Collect physiological signals

    Device: Sacral Neuromodulation

Interventions

  • DeviceSacral Neuromodulation

    Sacral neuromodulation delivers electrical stimulation to a sacral nerve

06

What researchers measure

Primary outcomes

  1. Number of subjects with physiological signals collected at each timepoint

    The proportion of subjects with evaluable signals will be summarized at each timepoint

    Time frame: 1 day to 7 months

07

Study locations

5 of 7 sites recruiting
  • Indiana University Health Methodist Research Institute
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Andi Nowakowski · Contactamnowako@iu.edu · 317-278-6752
    • Charles Powell · Principal investigator
  • LSUHSC Department of Urology
    New Orleans, Louisiana 70112, United States
    Withdrawn

    Not enrolling at this site.

  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
    Recruiting
  • Mayo Clinic Urology/Urogynecology Department
    Rochester, Minnesota 55905, United States
    Recruiting
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
    • Paul Cinicola · Contactpaul.cinicola@uhhospitals.org · 216-286-7376
    • David Sheyn · Principal investigator
    • Adonis Hijaz · Sub investigator
    • Joseph Henderson · Sub investigator
    • Anne Sammarco · Sub investigator
  • OhioHealth Physician's Group Urology
    Hilliard, Ohio 43026-2050, United States
    Recruiting
  • DHR Health Institute for Research and Development
    Edinburg, Texas 78539, United States
    Completed

    Not enrolling at this site.

08

References and documents

Publications

  • Goudelocke C, Ruiz H, Powell CR, Sheyn D, Linder BJ, Shah K, Villegas G, Henderson J, Sammarco AG, Offutt SJ, Keller DUJ, Bittner KC, Bink H, Merlo I, Slopsema JP, Nikolas LJ. Sensing in Sacral Neuromodulation: Objective, Individualized Stimulation Response Thresholds Directly From the Lead. Neurourol Urodyn. 2026 Sep 25. doi: 10.1002/nau.70443. Online ahead of print. PubMed 42788388 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Dec 2026, 59 months after the start.

Of 41 industry-sponsored interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's planned 59 months is above that.

Counting every sponsor, half of 175 studies reached it within 19 months; a quarter within 10 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Jan 21, 2022
StartActual
Jan 18, 2022
Primary completionEst.
Dec 18, 2026
CompletionEst.
Dec 18, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42788388 ↗
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University Hospitals Cleveland Medical Center · Cleveland, United StatesContact H•••@uhhospitals.org · •••8830→p•••@uhhospitals.org · •••7376
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42788388 ↗
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University Hospitals Cleveland Medical Center · Cleveland, United StatesContact H•••@uhhospitals.org · •••8830→p•••@uhhospitals.org · •••7376
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05200923
Lead sponsor
MedtronicNeuro
Responsible party
Sponsor
First posted
Jan 21, 2022
Start date
Jan 18, 2022
Primary completion
Dec 18, 2026 (estimated)
Completion
Dec 18, 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

Katherine Peterson
Contact
katherine.r.peterson@medtronic.com
414-704-4065
Katherine Peterson
study director · Medtronic Pelvic Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion